KemPharm: The Secondary Offering From Hell
KemPharm shares were crushed on Friday after the company announced that it would be conducting a secondary offering.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 120
SI-Bone Announces Potential Pricing for IPO
Medical device company SI-Bone intends to list 6 million shares in an initial public offering valued up to more than $103 million.
Why Vaxart’s New Flu Vaccine Is So Great
Vaxart shares more than doubled on Thursday after the company announced positive results from the midstage trial of its influenza oral tablet vaccine.
Why Arrowhead Pharma’s New Agreement Is a Big Deal
Arrowhead Pharmaceuticals shares stumbled on Thursday after it announced a license and collaboration agreement with Janssen Pharmaceutica, a subsidiary of Johnson & Johnson.
Clovis Wins Big With FDA Update
Clovis Oncology shares jumped on Tuesday after the U.S. Food and Drug Administration (FDA) gave a critical update.
Pfizer Announces Big Changes at the Top
Pfizer shares hit multiyear highs and nearly an all-time in Monday’s session after the pharma giant announced a succession plan for its CEO.
Why Akorn Shares Were Halved
Akorn shares were crushed early on Monday after a Delaware judge ruled that German health care group Fresenius could walk away from its $4.75 billion merger deal.
Major Biopharma Catalysts on October’s FDA Calendar
Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of October.
Equillium Prepares for IPO
Biotechnology company Equillium has amended its filing with the SEC regarding its initial public offering.
Why Aldeyra Could Have Another 100% Upside, or More
Two research firms have called for major upside ahead Aldeyra Therapeutics, even after the big pop in the stock on Wednesday.
US DEA Updates Schedule of Cannabidiol for GW Pharmaceuticals
GW Pharmaceuticals shares made a solid gain on Thursday after it received a critical update from the DEA.
Protagonist Therapeutics Wins FDA Fast Track
Protagonist Therapeutics shares made a solid gain on Thursday after the company announced a key update from the FDA.
Why Geron Is Getting Crushed
Geron shares were absolutely crushed on Thursday morning after it was announced that Janssen Biotech has terminated the 2014 collaboration and license agreement with the firm.
Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now
Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term, and the sector that rated highest was biotechnology.
Verastem’s Copiktra Breaks Into China With New Licensing Deal
Verastem shares saw a handy gain on Wednesday after the company set an exclusive licensing agreement to develop and commercialize Copiktra.